

# Autophagy Shapes Inflammation

László Fésüs, Máté Á. Demény, and Goran Petrovski

## Abstract

Autophagy is a basic cell biological process ongoing under physiologic circumstances in almost all cell types of the human organism and upregulated by various stress conditions including those leading to inflammation. Since autophagy affects the effector cells of innate and adaptive immunity mediating the inflammatory response, its activity in these cells influences the antimicrobial response, the development of an effective cognate immune defense, and the course of the normal sterile inflammatory reactions. The level of autophagic activity may determine whether tissue cells die by apoptosis, necrosis, or through autophagy, and, as a consequence, whether the clearance of these dying cells is a silent process or results in an inflammatory response. Loss or decreased autophagy may lead to necrotic death that can initiate an inflammatory reaction in phagocytes through their surface and cytosolic receptors. Engulfment of certain cells dying through autophagy can activate the inflammasome. The intertwining regulatory connections between inflammation and immunity extend to pathologic conditions including chronic inflammatory diseases, autoimmunity and cancer. *Antioxid. Redox Signal.* 14, 2233–2243.

## Introduction

AUTOPHAGY IS A UBIQUITOUS EUKARYOTIC PROCESS essential for embryonic development, cytoprotection, and survival during stress conditions, particularly during starvation (13). It is composed of macroautophagy, microautophagy (40), and chaperone-mediated autophagy (62) that differ in the delivery mode to lysosomes. This review is primarily concerned with macroautophagy (hereafter referred to as autophagy). It involves sequestration of cytoplasmic constituents, damaged proteins, organelles, and pathogens in a double-membrane bound autophagosome targeting these materials for degradation in the lysosomes and recycling the constituent molecules (67). The basic molecular elements of autophagy, as revealed mainly through yeast genetic studies, are evolutionarily conserved but regulated by divergent regulatory elements and specific factors in higher eukaryotes. The autophagic machinery contains at least 20 autophagy (Atg) proteins recruited after the initiation of autophagosome nucleation through signal integrator macromolecular complex which involves beclin-1, class III phosphatidylinositol-3-kinase (PI3K), and other proteins. Inflammation is a defense reaction provoked by microbial pathogens or tissue damage triggering influx of neutrophils and monocytes to the site of injury. The inflammatory reaction is initiated mainly by the innate immune system utilizing its germ-line encoded pattern recognition receptors that are capable of recognizing either

pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) through either Toll-like receptors (TLRs) or NOD (nucleotide oligomerization domain)-like receptors (NLRs). Detection of endogenous or exogenous ligands by cells lead to receptor activation, formation of multiprotein signal transduction cascades, upregulation and secretion of pro-inflammatory mediators, and subsequent induction of the adaptive immune response (68). Among the pro-inflammatory mediators, interleukin (IL) 1 lies in the center of the inflammatory response mediating fever, prostanoïd generation, neutrophil recruitment, lymphocyte activation, and induction of other inflammatory cytokines such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) and IL-6 (65). Among the IL-1 family members, IL-1 $\alpha$  and IL-1 $\beta$  are the most prominent operating through the IL-1 type I receptor (IL-1RI). While IL-1 $\alpha$  is constitutively expressed and cleaved by calpain, IL-1 $\beta$  is synthesized as pro-IL-1 $\beta$  and cleaved by caspase 1 to generate the active and secreted IL-1 $\beta$ . Caspase-1 is activated by the inflammasome complex which contains NOD-like family members such as NLRP3 (NLR family, pyrin domain containing 3, also known as NALP-3), the adaptor protein ASC, and procaspase-1 (85). It is generally accepted that two signals are required for IL-1 $\beta$  secretion. In the priming phase the expression of pro-IL-1 $\beta$  and other components of the inflammasome is efficiently induced by PAMPs and DAMPs acting mainly through the NF- $\kappa$ B dependent transcriptional mechanism, similar to how TNF- $\alpha$  and IL-6

Department of Biochemistry and Molecular Biology, The Apoptosis and Genomics Research Group of the Hungarian Academy of Sciences, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.

induction is driven by TLRs (TLR4, TLR2, TLR3, TLR7), NOD2, muramyl dipeptide, or cytokines (2, 20, 21). The inflammasome can be activated by a second signal, such as whole pathogens, PAMPs, some bacterial toxins, environmental particulate agents (silica or asbestos fibers), and endogenous danger signals (e.g., ATP, monosodium urate) leading to IL-1 $\beta$  secretion, which can turn on a full blown inflammatory reaction acting on target cells and inducing further cytokine response (65).

There is much evidence of a complex interaction between the autophagy pathway and diverse aspects of innate and adaptive immunity, including pathogen resistance, antigen presentation, tolerance, and lymphocyte development, as well as the negative regulation of cytokine signaling (reviewed recently by (101)). The present review focuses on the importance of autophagy in the primary inflammatory response, particularly how the level of autophagic activity in the immune competent cells influences the inflammatory reaction and why clearance and pro-inflammatory character of dying cells are determined by the interplay between autophagic and cell death pathways.

### The Autophagy Pathway

Autophagy begins when a flat membrane cisterne called the phagophore or isolation membrane, which is thought to originate from the ER (1, 15), the trans Golgi, late endosomes or infrequently from the nuclear membrane, wraps around a portion of the cytosol forming a vacuole called the autophagosome (Fig. 1). Autophagosomes undergo maturation involving fusion with endosomes and eventually with lysosomal vesicles, where they deliver their cargo. The cargo is then digested by lysosomal hydrolases and the catabolites are transported to the cytoplasm for reutilization by permeases and translocases (26, 66). In the nucleation step, a complex containing Beclin-1, the PI3K, Vps34, Atg14, and Atg15 marks the earliest form of the phagophore. Atg5 is conjugated with Atg12 by Atg7 and Atg10. The Atg5–12 complex forms a large multimeric complex at the phagophore with Atg16L1. This localizes mainly to the convex surface of the isolation membrane and it may determine the curvature of the forming autophagosome through a protein lattice (97), however its exact function is not understood. It also marks the site for microtubule-associated protein1 light chain 3 (LC3) lipidation. LC3 (also known as Atg8) is proteolytically activated by Atg4, losing five C-terminal amino acids. The ubiquitin-activating and –carrier proteins, Atg7 and Atg3, couple the exposed terminal glycine of LC3 to phosphatidyl-ethanolamine (PE), which is inserted in the forming autophagosomal membrane or phagophore. The membrane is then elongated and sealed. In the maturation step, autophagic vacuoles fuse with early and late endosomes as well as lysosomes. The process probably begins with homotypic fusion of endosomes and this large multivesicular structure fuses with the autophagosomes, giving rise to what is called the amphisome. The Beclin-1–Atg14 complex and another Beclin-1 complex with UV radiation resistance-associated gene protein (UV-RAG) drive this step by activating a complex termed HOPS (homotypic vacuole fusion and protein sorting), which acts as a Rab7 guanine nucleotide exchange factor (54). Finally amphisomes fuse with dense lysosomes acquiring lysosomal membrane proteins and degradation enzymes and their pH

becomes slightly acidic (~5.7). Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins such as vesicle-associated membrane protein 8 (VAMP8) and Vti have been suggested to mediate the actual membrane fusion events.

### Influence of Autophagy on the Inflammatory Response in the Immune Effector Cells


#### The antimicrobial response

The most direct way in which autophagy influences inflammation is the autophagic capture of intracellular microbes and their elimination via autolysosomes in the process sometimes referred to as xenophagy (12). There are specific adapter molecules targeting bacteria for capture by the autophagolysosomes (106, 107) and viruses, as well as bacteria-developed factors to counter autophagy (reviewed by (12)). It appears that autophagy may have evolved as one of the first autonomous defense mechanisms in eukaryotes working against invading microbes as phagocytosis of different extracellular pathogens resembles very much the machinery for autophagic clearance of intracellular organelles via the autophagolysosomal system (50). It also has been shown that autophagy can serve also as a back-up mechanism for phagocytosis of *Francisella tularensis*, *Listeria monocytogenes*, *Mycobacterium tuberculosis*, *Salmonella enterica*, *Shigella flexneri*, *Streptococcus pyogenes*, or *Toxoplasma gondii* (14, 52, 79). TLRs regulate autophagy induction (reviewed by (101)) which is needed for efficient autophagic control of intracellular pathogens. On the other hand, microbial components initiate the signal cascade for cytokine induction through the various TLRs.

One of the functions of autophagy is the delivery of foreign antigen material to innate and adaptive immunity (46, 51, 83). Autophagy may exert cytoprotective and pathogen trafficking functions in infected cells by activating Atg5 which is required for delivery of viral nucleic acids to the endosomal TLR7 which further activates type I interferon (IFN) signaling (52). Autophagy can be utilized in adaptive immunity by the major histocompatibility complex (MHC) class II antigen presentation system for endogenous antigens (e.g., Epstein Barr viral antigens) (51). The latter holds great potential for future vaccine development by which vaccine efficacy would be increased through improvement of the T helper cell response (52). After viral infection, autophagy is activated by the double-stranded viral RNA-activated protein kinase R (PKR) which phosphorylates and therefore activates the eukaryotic translation initiation factor-2 $\alpha$  (eIF-2 $\alpha$ ), this in turn inhibits viral replication (90, 94). Alternatively, the receptor-interacting protein (RIP) pathway can induce autophagy in response to viral infection (7).

#### Autophagy impinges on inflammation through regulation of intracellular ROS production

A common theme in the background of the phenotypes resulting from the genetic ablation of Atg5, Atg7, Atg12, and Atg16L1 appears to be the accumulation of dysfunctional mitochondria in the absence of autophagy, which results in elevated release of reactive oxygen species (ROS) (Fig. 1). Autophagy has in many instances been reported to regulate ROS production negatively by decreasing the mitochondrial



**FIG. 1. Autophagy affects inflammation through mitochondrial quality control and regulation of ROS production.** Defects in autophagy result in the accumulation of dysfunctional mitochondria and peroxisomes, which leak ROS into the cytoplasm. ROS are sensed by RLRs (RIG-I/IPS-1 complex) and the NALP3 inflammasome in the cells of the innate immune system and they release pro-inflammatory cytokines. Direct oxidative damage to proteins and organelles combined with reduced metabolic tolerance can result in necrotic cell death, release of damage associated molecular patterns (DAMPs), and inflammation. ASC, apoptosis-associated speck-like protein containing a caspase recruitment domain; IPS, interferon  $\beta$  promoter stimulator 1; IRF, interferon regulatory transcription factor; NALP, NACHT-LRR-PYD-containing protein; RIG, retinoic acid inducible gene; RLRs RIG-I-like receptors; ROS, reactive oxygen species; UV radiation resistance-associated gene protein (UVRAG).

mass and eliminating leaky mitochondria and peroxisomes (3, 81). These radicals are known to be activators both of RIG (retinoic acid inducible gene)-I-like receptors (RLRs) (93) and NLRP3 (61) driving the production of more IFN and interleukins. The RLRs, cytoplasmic RNA-sensors, RIG-I, and melanoma-differentiation associated gene (MDA5), signal through interferon  $\beta$  promoter stimulator 1 (IPS-1), which activates two major signaling pathways. It stimulates the I $\kappa$ B kinase (IKK) complex, thereby eventually activating NF- $\kappa$ B and through the IKK-related tank-binding kinase (TBK) 1 and IKK $\epsilon$  it activates interferon regulatory transcription factor (IRF) 3/7 and IFN type I production. IPS1 is an outer membrane mitochondrial protein and its amount increases with increased number of mitochondria. This alone is not enough to account for amplified signal transmittance on these path-

ways. It has been hypothesized that an inhibitor of RLR signaling might become inactivated upon oxidation or, on the contrary, oxidation enables a positive-regulator of RLRs. It is also conceivable that ROS-level sensing proteins are involved in RLR signaling in a presently unknown way (93).

#### *Inflammasome activation is under autophagy control*

TLR4 agonists, particularly lipopolysaccharide (LPS), cannot induce inflammasome activation and IL-1 $\beta$  secretion in wild-type macrophages. When genes of the autophagy regulators Atg16L1 or Atg7 are deleted or a chemical inhibitor of autophagy is applied, LPS-dependent inflammasome activation occurs suggesting that autophagy controls inflammasome activation and can limit production of the inflammatory



cytokines IL-1 $\beta$  and IL-18 (82). In accordance with this finding, autophagy also inhibits pyroptosis, a specialized form of cell death occurring after *Shigella* infection and mediated by the NLR family member Ipaf through caspase-1 activation (91). Autophagy induction also associates with transient resistance to pyroptosis, and infection of macrophages with *Shigella* leads to induction of autophagy, which dramatically increases during absence of caspase-1 or Ipaf, showing an additional level of complexity in the links between inflammasome and autophagy. Though several molecular explanations have been provided, the mechanism of autophagy-dependent inflammasome inhibition is not clear at present. Inflammasomes may be directly degraded through autophagy (31). A more likely explanation is negative regulation of ROS generation by autophagy (81, 82). It should be also noted that ROS stimulate autophagy (8,35) probably effectuating a negative feedback loop.

#### *The transglutaminase connection*

In the case of other proteins linked to autophagy and inflammation, the connection between the role(s) of transglutaminase 2 (TG2) is even less elucidated. This multifunctional enzyme has recently been implicated in autophagosome maturation (9). In particular, TG2  $-/-$  mouse embryonic fibroblasts accumulated GFP-LC3 labeled vacuoles representing autophagosomes, likely due to failure to efficiently merge with lysosomes. This was partially dependent on the cross-linking function of TG2. This enzyme had formerly been implicated in liposome fusion (19), though the phenomenon at hand might involve a more intricate interaction between TG2 and autophagosomal proteins. An earlier study found that in pancreatic cancer cells, constitutive activation of protein kinase C (PKC)  $\delta$  suppressed autophagy through induction of TG2 (72). Using specific inhibitors, these authors suggested that TG2 activates PI3K and mammalian target of rapamycin (mTOR), while inhibiting Beclin-1. The exact mechanism though has not been explained and these two antagonistic observations await reconciliation.

TG2  $-/-$  mice are partially protected from LPS-induced sepsis. The serum level of IL-6 and granulocyte colony-stimulating factor (G-CSF) in these animals fell to many-fold lower than that of their wild-type litter mates by 24 hours following a single injection of LPS, although their basal or maximal levels and induction kinetics did not differ significantly (17). Contrastingly, others have found that TG2  $-/-$  macrophages respond to LPS stimulation with significantly higher IL-6 and TNF production (Zsuzsanna Szondy, University of Debrecen, Debrecen, Hungary; personal communication, unpublished data). Activation of NF- $\kappa$ B plays a key role in the inflammatory process by inducing the transcription of pro-inflammatory mediators. TG2 had been shown to directly activate NF- $\kappa$ B by polymerizing I $\kappa$ B $\alpha$  (48) and also TG2 induced the expression of NF- $\kappa$ B (58). It is therefore possible that the endotoxin resistant phenotype of TG2  $-/-$  animals is related to a role of the protein other than its involvement in autophagy.

TG2-deficient macrophages show defects in phagocytosis of apoptotic cells, which is either due to their defective transforming growth factor beta (TGF $\beta$ ) secretion (92) or to formation of partially functional phagocyte portals (96). TG2, as an adaptor is supposed to bridge milk-fat globule EGF-factor (MFGE8) to integrin  $\beta$ 3 on the surface of macrophages

creating a docking site for the apoptotic corpse. It has been attributed to this defect that TG2  $-/-$  animals develop autoimmune glomerulonephritis (92) later in life. As we have seen, improper autophagic capacity can also cause a disturbance in self tolerance. It needs further investigation whether this link is applicable to TG2.

#### *Autophagic death of immune competent cells*

Although autophagy is basically a pro-survival mechanism, one of the cell death modalities is initiated by an increased rate of autophagy that may lead to irreversible molecular and structural events triggering caspase-independent autophagic death (27, 45). Autophagic death of immune competent cells, particularly of macrophages, may compromise defense against infection, but could also be beneficial in controlling the level and duration of inflammation. It has been reported that there are conditions when autophagy contributes to caspase-independent macrophage cell death involving TIR-domain-containing adapter-inducing interferon- $\beta$  (TRIF), RIP1, ROS production, and activation of poly(ADP-ribose)polymerase activation (105). In the adaptive phase of the immune response, activation-induced death of CD4 $^{+}$  T cells is partially mediated by autophagy: IFN- $\gamma$  may induce autophagic death of these cells (18) and knockdown of *beclin-1* or *atg5* results in decreased death rate of CD4 $^{+}$  T cells upon growth factor withdrawal (53) or presence of immunodeficiency virus envelope protein (16).

#### **Importance of Autophagy in Dying Cells in Determining Anti- or Pro-Inflammatory Response in Phagocytes**

##### *Autophagy during apoptotic death*

Autophagy is active during programmed cell death when developmental processes require massive cell elimination and frequently activated in cells dying by apoptosis. It is involved in generation of energy-dependent engulfment signals in apoptotic cells, particularly the secretion of the find-me signal lysophosphatidylcholine and exposure of phosphatidylserine on the surface of dying cells (76). Such a role of autophagy in apoptotic cell clearance may have general significance and in case of deficient or inhibited autophagy, the clearance of apoptotic cells becomes inefficient, leading to secondary necrosis of the dying cells. Necrotic cells, unlike the anti-inflammatory apoptotic ones, are potent inducers of the inflammatory response in nearby immune competent cells.

##### *Autophagy and necrosis*

When cells die massively *in vivo* by necrosis, they stimulate a robust inflammatory response (44, 57). Damaged cells release DAMPS, such as high-mobility group box 1 protein (HMGB1) and heat shock proteins that alert the innate immune system via stimulating TLRs. It has been also reported that necrotic cells produced by pressure disruption, hypoxic injury, or complement-mediated damage can trigger a sterile inflammatory response through activating the NLRP3 inflammasome (36). Cells with active autophagy when killed by epidermal growth factor targeted diphtheria toxin, selective release of the immune stimulator HMGB1 occurs without sign of classical necrosis (95). Autophagy promotes necrosis in apoptosis-deficient cells in response to endoplasmic reticulum (ER) stress (99), a condition often associated with human

diseases (60). This probably occurs because in cells where excessive ER stress fails to induce apoptosis, the stressing situation keeps accumulating to the point where autophagy is massively induced, leading to cell damage and necrosis. Under defective apoptosis conditions, a cell death mechanism that required autophagy was mediated through RIP-1 kinase activity inducing programmed necrosis called necroptosis (32). This can be utilized in the treatment of childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance by induction of autophagy-dependent necroptosis with the help of a chemical agent (4) release active beclin-1 and inhibiting the anti-autophagic activity of mTOR.

#### *Clearance of cells dying through autophagy may lead to inflammasome activation*


Recently, we discovered that cells undergoing autophagic cell death can induce a pro-inflammatory response in human macrophages (73, 74): it was shown by gene array and cytokine secretion analysis that a pro-inflammatory response involving the secretion of IL-6, TNF $\alpha$ , and IL-8 and the anti-inflammatory cytokine IL-10 is generated in human macrophages engulfing MCF-7 cells undergoing autophagic cell death. This finding was surprising, since autophagic dying cells are morphologically and molecularly very similar to apoptotic ones, but the clearance of apoptotic cells is a silent process (56)—apoptotic cells can inhibit pro-inflammatory responses induced by LPS in phagocytes. We could clarify that while cells dying through autophagy can block LPS-induced release of pro-inflammatory cytokines, they can induce IL-1 $\beta$  production and release, and this initiates further pro-inflammatory cytokine response in a paracrine fashion (Fig. 2). It appears that during phagocytosis of autophagic dying cells, ATP acting through its receptor initiates K $^{+}$  efflux, inflammasome activation, and IL-1 $\beta$  secretion, which in turn initiates further upregulation and release of pro-inflammatory cytokines, such as TNF $\alpha$  and IL-6. One of the several mutually

not exclusive mechanisms of inflammasome activation involves extracellular ATP working through the p2X $_7$  receptor, an ATP-gated ion channel, and rapid K $^{+}$  efflux—the inflammasome sensing the low intracellular potassium level (84). ATP results in opening of pannexin-1-mediated pore through which intracellular compartments-to-cytosol translocation can occur. Our results show that inflammasome activation by autophagic dying cells could be suppressed by high concentration of K $^{+}$  (data not shown), which is characteristic for NLRP3 (21, 33). Following the engulfment of autophagic dying cells by macrophages, ATP appears in the extracellular space, resulting in the initiation of the above described sequence of events. Autophagic dying cells also may produce activator molecules such as cathepsin B (33), a known inflammasome activator, while being degraded in the phagolysosomal compartment. In addition, reactive oxygen species (ROS) generated in response to endogenous danger signals from engulfed autophagic dying cells may result in activation of the NLRP3/inflammasome complex (85, 108).

#### *Autophagy in the dying cells promotes cross-presentation*

MHC class II presentation of peptides derived from cytosolic proteins results from autophagy (100). Macroautophagy can deliver antigens into autophagosomes for processing by acidic proteases and chaperone-mediated autophagy can translocate endogenous antigens processed by cytoplasmic proteases into the endosomal network to intersect MHC class II (89). In a study by Uhl *et al.* (98) using virally infected wild-type and apoptosis-deficient Bax/Bak(-/-) fibroblasts as a source of cell-associated antigen, immunization with cells undergoing autophagy before cell death was found to be superior in facilitating the cross-priming of antigen-specific CD8 $^{+}$  T cells and silencing Atg5 expression inhibited priming. They interpreted this autophagic death to be a novel form of 'immunogenic death' with the enhanced priming efficiency

**FIG. 2. Proposed model for the mechanism of IL-1 $\beta$  cytokine release by macrophages.** Cells dying through autophagy (AU) can block Toll-like receptor (TLR)-dependent pro-inflammatory response but may initiate the activation of the inflammasome in macrophages. Extracellular ATP release and P2X $_7$ R activation, intracellular K $^{+}$  depletion, and ROS production, as well as lysosomal cathepsin B release, all work through a complex mechanism towards inflammasome activation and IL-1 $\beta$  cytokine release. AU, cells dying through autophagy; LPS, lipopolysaccharide; NALP, NACHT-LRR-PYD-containing protein; PS, phosphatidylserine; ROS, reactive oxygen species; TLR, Toll-like receptor.



being a result of persistent MHC I cross-presentation and the induction of type I interferons. In another study by Lee *et al.* (47), mice with conditional deletion in Atg5 in dendritic cell (DC) showed impaired CD4<sup>+</sup> T cell priming after herpes simplex virus infection and succumbed to rapid disease. The most pronounced defect of Atg5(-/-) DCs was in the processing and presentation of phagocytosed antigens inducing TLR stimuli for MHC class II, the cross-presentation of peptides on MHC I remaining intact in the absence of Atg5. These results suggest that autophagy can influence cross-priming, and targeting the autophagy cascade may provide a better therapeutic/vaccination strategy for achieving potent cross-priming of viral and tumor-specific CD8<sup>+</sup> T cells. New vaccination strategies have been based upon this phenomenon, aimed at improving the targeting of antigens to dendritic cells, promoting cross-priming, improving peptide binding to class I molecules, and targeting antigens to both the class I and the class II pathways.

### Significance of Autophagy in Human Inflammatory Diseases

#### Crohn's disease

Crohn's disease (CD) is one of the two major forms of inflammatory bowel disease, which can affect the small bowel and/or the colon. It is characterized by severe chronic inflammation extending across all layers of the intestinal wall. Among etiological factors, genetic predisposition and an infectious cause, particularly an aberrant response to the commensal gut flora, have long been suspected.

Genome-wide association studies have linked two autophagy related genes to CD, Atg16L1 and immunity-related GTPase M (IRGM) (29, 64, 80). The polymorphism associated with CD in Atg16L1 is a single amino acid mutation (T300A) in one of the WD40 repeats, which is unlikely to delete Atg16L1 function. WD40 repeats are propeller like protein-protein interaction platforms and the five of them in Atg16L1 are currently not known what interact with. Atg16L1 T300A has been shown to be less stable in the wake of infection with invasive enteric bacteria. Accordingly, chimeric mice with Atg16L1-deficient hematopoietic cells do not develop spontaneous colitis and survive like their wild-type counterparts in most respects under normal conditions. However, in response to dextran sulfate sodium (DSS)-induced experimental colitis, these chimeric animals die rapidly due to a more severe inflammation and ulceration of the distal colon (82). The levels of IL-1 $\beta$  and IL-18 were significantly elevated in the sera of these animals and their mortality could be reduced by the injection of IL-1 $\beta$  and IL-18 neutralizing antibodies. The importance of Atg16L1 in altered cytokine production in CD is supported by another study, which found enhanced expression of acute phase reactants and adipokynes in Paneth cells of Atg16L1 hypomorphic mice. Paneth cells are found in the crypts of the ileum and sometimes the colon and they perform secretory and phagocytic functions. They are thought to regulate the bacterial flora locally and to systemically influence pro- and anti-inflammatory processes. The polymorphism associated with the immunity related GTPase (also called p47 GTPases), IRGM occurs in the upstream regulatory region of the gene and causes reduced expression of the protein in CD (64). The precise role of IRGM in autophagy is not yet understood, nevertheless it has been shown to play a role in

autophagic control of intracellular pathogens, *M. tuberculosis*, in particular (88). The much more extensive IRG family in mouse has, however, multiple roles, for example in phagosome acidification and in the maturation and the parasitophorous vacuole membrane (34). How analogous functions may contribute to the pathogenesis of CD remains to be deciphered.

#### Lysosomal storage diseases

Lysosomal storage diseases (LSDs) are a group of over 40 genetic conditions, most of which are caused by deficiency of lysosomal hydrolases. Lysosomal storage diseases are now frequently interpreted as autophagic disorders (77, 87) and in recent years the pathogenesis of many neurodegenerative storage disorders have been rethought with a special focus on autophagy (5, 22, 23, 41). The LSDs in which autophagy has been studied include multiple sulfatase deficiency, mucopolysaccharidosis Type IIIA, GM1-gangliosidosis, Pompe disease, Niemann-Pick disease Type C, neuronal ceroid lipofuscinosis, mucopolipidosis Type IV, and Danon disease (77). Impaired fusion between autophagosomes and lysosomes results in the accumulation of polyubiquitinated proteins and lipids and also defective mitochondrial turnover and generation of high levels of ROS, which in turn elicits an inflammatory response and can lead to systemic inflammation (86).

#### Neurodegeneration and neuroinflammation

Inactivating mutations of *parkin-1* are linked to early-onset cases of Parkinson's disease (PD). The specific pathological features of PD are the loss of neurons from the pars compacta of the substantia nigra and the consequent disturbance of dopaminergic signaling in the striatum. The wasting neurons show signs of mitochondrial dysfunction and oxidative stress, contain inclusions of ubiquitinated proteins and organelles (Lewy bodies), and the affected brain territories are surrounded by an infiltrate of neurotoxic microglia and activated astrocytes, indicating a chronic neuroinflammatory process (25). The ubiquitin ligase, Parkin, is a mitochondrial protein that recently has been shown to be directly responsible for mitophagy (a subtype of autophagy in which turnover of damaged mitochondria occurs via the autophagolysosomal pathway) (49). Lee *et al.* found that cells expressing mutant Parkin failed to recycle their mitochondria when they were damaged. Parkin, an ubiquitin E3-ligase, is selectively associated with depolarized or impaired mitochondria through PTEN-induced putative kinase (PINK) 1 (10, 63) and promotes their autophagy (70, 71). Now we learn that Parkin-mediated ubiquitination of these organelles is required to recruit the autophagy proteins histone deacetylase (HDAC) 6 and p62/SQSTM1 (24). HDAC6 and p62/SQSTM1-dependent transport to perinuclear aggregates concentrates toxic proteins and dysfunctional organelles for subsequent removal by autophagy and Parkin fails to clear mitochondria in either HDAC6 or p62 deficient cells. Accordingly, Parkin might protect neurons by promoting the clearance of dysfunctional mitochondria, which could produce ROS, oxidative damage, cell death, and inflammation.

Targeted ablation of other autophagy genes in mice also leads to cell death in the central nervous system and neurodegeneration (30, 42) with inflammation. Post mitotic cells



such as neurons or muscle cells may be particularly sensitive to accumulation of undegraded material as these cells cannot dilute the accumulated material by cell division.

#### *Paget's disease of bone*

Paget's disease of bone (PDB) is a mostly focal, less frequently systemic, chronic condition characterized by excessive resorption of bone by atypical hyperactive osteoclasts. At later stages the resorbed bone is replaced with coarse-fibered, dense trabecular, haphazardly organized bone accompanied by a fibrous, hypervascularized marrow-space, a picture resembling abnormal tissue remodeling after inflammation. Between 10%–50% of patients with familial PDB and between 5–30% of patients with "sporadic" PDB carry mutations in p62/SQSTM1 (78). All PDB-causing mutations impair ubiquitin binding (6). The lack of p62/SQSTM1 severely reduced NF- $\kappa$ B activation in response to the inflammatory cytokines TNF $\alpha$  and IL-1 (69), and the nerve growth factor (NGF), which signal through atypical protein kinase C (aPKC) isoforms, such as  $\zeta$ PKC and  $\iota$ PKC. p62/SQSTM1 interacts with RIP and TNF-receptor associated factor (TRAF) 6, which are important adaptor molecules in the signaling pathways activated by TNF-receptor (TNFR), IL-1R, and p75 NGF-receptor (NGFR). In addition, aPKCs interact with p62/Sequestosome 1 (SQSTM1) directly through its (atypical PKC interaction domain) AID region. Inhibition of the p62/SQSTM1-aPKC interaction blocked NF- $\kappa$ B activation in cell cultures, inhibited NGF-induced neuronal survival and differentiation (103), and displayed potent anti-inflammatory and anti-tumor activities in different animal models (69). Although the disruption of the ubiquitin binding activity of p62/SQSTM1 is undoubtedly necessary for PDB, it is still unclear whether the removal of components of the NF- $\kappa$ B signaling pathway through autophagy in osteoclasts is the responsible molecular event.

#### *Arthritis*

FLIP (also known as caspase 8 or FADD-like anti-apoptotic molecule) is overexpressed in macrophage-like cells in the synovial tissue of inflamed joints in juvenile idiopathic arthritis (JIA) and its expression positively correlates with the severity of inflammation (104). It has been suggested that upregulation of pro-inflammatory FLIP extends the lifespan of inflammatory cells and thereby procrastinates the resolution of the process. FLIP is reported to promote autophagy and to ameliorate the energy homeostasis of cells (49). It will require further investigation to resolve if and to what extent FLIP's pro-autophagy effect contributes to survival of the pro-inflammatory cell population in the inflamed joints.

#### *Loss of autophagy may promote inflammation and tumorigenesis as a result of a sustained high dead cell burden*

Autophagy in tumors is thought to serve the survival of tumor cells (11) by improving stress tolerance, and maintaining viability in an environment where nutrients are sparse due to rapid growth and an insufficiently developed vasculature, and where without autophagy cells would succumb to apoptotic or necrotic demise (37–39, 102). Autophagic tumor cells can reduce in size and become dormant,

although retaining a proliferative capacity for better times. By rescuing tumor cells, autophagy prevents inflammation resulting from necrotic cells (28, 59). This can have ambivalent consequences, considering that many current cancer therapeutics boost autophagy. On one hand, it is harmful as the inflammatory reaction could contribute to the elimination of cancer cells. On the other hand, sustained inflammation inside the tumor would also top up proliferative signals, such as IL-1, IL-6, TNF, IL-11, and IL-23. Tumor-associated inflammatory macrophages also promote neo-vascularization through the secretion of IL-8, CXCL1, CXCL8, and VEGF. Inactivation of a number of pro-autophagy genes (*beclin-1*, *bif-1*, *atg4*) renders mice tumor prone (55, 75). Apoptosis-defective tumors in which autophagy was simultaneously inactivated by Akt activation or allelic disruption of *beclin-1* display chronic necrosis, inflammation, dramatic macrophage infiltration, NF- $\kappa$ B activation, and cytokine production as opposed to tumors in which autophagy is functional (11). Chronic cell death causes inflammation in autophagy-defective tissues, for example in the liver of *Atg7* null mice (43).

#### **Conclusion**

As it has been discussed above in detail, autophagy can influence inflammatory reactions by several ways in a cell-intrinsic manner, affecting either positively or negatively pro-inflammatory signaling within immune effector cells when they encounter PAMPS or DAMPS. In the context of the inflamed normal tissue, where nutritional supplies are running short, the inflammatory cells themselves might just as well fall back on supporting their functioning by means of autophagy. Its effect on cellular energy homeostasis, tolerance against cellular stress, and prevention or provocation of pro-inflammatory cell death can potentially determine the degree and duration of inflammation. Under certain conditions autophagic dying cells and autophagy-driven necrotic ones can provoke NLRP3 inflammasome activation in macrophages with concurrent caspase-1 activation and secretion of IL-1 $\beta$ , suggesting that some forms of autophagic death are pro-inflammatory and immunogenic in sharp contrast to immune-suppressing apoptotic cell death. This may have particular significance in tumor tissues where loss of apoptosis genes with a shift toward autophagic death frequently occurs, provoking inflammatory reaction which, in turn may contribute to either tumor cell proliferation or development of anti-tumor immune response. During the last couple of years, it has been revealed that polymorphism of autophagy genes and those which regulate autophagy is linked to susceptibility toward various inflammatory disorders including Crohn's disease, Paget's disease, and arthritis. With current technologies, animal models of such diseases can be developed to learn the molecular details of the specific pathogenetic processes and to understand how autophagy contributes to them. These efforts will lead to novel autophagy-targeted therapeutic interventions in cancer and chronic inflammatory disorders.

#### **Acknowledgments**

This work has been funded by grants from the Hungarian Scientific Research Fund [OTKA NI 67877, K 61868], an ETT grant from the Hungarian Ministry of Health and EU

[MRTNCT-2006-036032, MRTN-CT 2006-035624, LSHB-CT-2007-037730].

## References

1. Axe EL, Walker SA, Manifava M, Chandra P, Roderick HL, Habermann A, Griffiths G, and Ktistakis NT. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. *J Cell Biol* 182: 685–701, 2008.
2. Bauernfeind FG, Horvath G, Stutz A, Alnemri ES, MacDonald K, Speert D, Fernandes-Alnemri T, Wu J, Monks BG, Fitzgerald KA, Hornung V, and Latz E. Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. *J Immunol* 183: 787–791, 2009.
3. Bensaad K, Cheung EC, and Vousden KH. Modulation of intracellular ROS levels by TIGAR controls autophagy. *EMBO J* 28: 3015–3026, 2009.
4. Bonapace L, Bornhauser BC, Schmitz M, Cario G, Ziegler U, Niggli FK, Schafer BW, Schrappe M, Stanulla M, and Bourquin JP. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. *J Clin Invest* 120: 1310–1323, 2010.
5. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME, and Cotman SL. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. *J Biol Chem* 281: 20483–20493, 2006.
6. Cavey JR, Ralston SH, Sheppard PW, Ciani B, Gallagher TR, Long JE, Searle MS, and Layfield R. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. *Calcif Tissue Int* 78: 271–277, 2006.
7. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel M, Orenstein J, Moss B, and Lenardo MJ. A role for tumor necrosis factor receptor-2 and receptor-interacting protein in programmed necrosis and antiviral responses. *J Biol Chem* 278: 51613–51621, 2003.
8. Chen Y, Azad MB, and Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. *Cell Death Differ* 16: 1040–1052, 2009.
9. D'Eletto M, Farrace MG, Falasca L, Reali V, Oliverio S, Melino G, Griffin M, Fimia GM, and Piacentini M. Transglutaminase 2 is involved in autophagosome maturation. *Autophagy* 5: 1145–1154, 2009.
10. Dagda RK, Cherra SJ, 3rd, Kulich SM, Tandon A, Park D, and Chu CT. Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. *J Biol Chem* 284: 13843–13855, 2009.
11. Degenhardt K, Mathew R, Beaudoin B, Bray K, Anderson D, Chen G, Mukherjee C, Shi Y, Gelinas C, Fan Y, Nelson DA, Jin S, and White E. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. *Cancer Cell* 10: 51–64, 2006.
12. Deretic V. Autophagy in infection. *Curr Opin Cell Biol* 22: 252–262, 2010.
13. Deretic V. Multiple regulatory and effector roles of autophagy in immunity. *Curr Opin Immunol* 21: 53–62, 2009.
14. Dorn BR, Dunn WA, Jr., and Prokulske-Fox A. Bacterial interactions with the autophagic pathway. *Cell Microbiol* 4: 1–10, 2002.
15. Dunn WA, Jr. Autophagy and related mechanisms of lysosome-mediated protein degradation. *Trends Cell Biol* 4: 139–143, 1994.
16. Espert L, Denizot M, Grimaldi M, Robert-Hebmann V, Gay B, Varbanov M, Codogno P, and Biard-Piechaczyk M. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. *J Clin Invest* 116: 2161–2172, 2006.
17. Falasca L, Farrace MG, Rinaldi A, Tuosto L, Melino G, and Piacentini M. Transglutaminase type II is involved in the pathogenesis of endotoxic shock. *J Immunol* 180: 2616–2624, 2008.
18. Feng CG, Zheng L, Jankovic D, Bafica A, Cannons JL, Watford WT, Chaussabel D, Hieny S, Caspar P, Schwartzberg PL, Lenardo MJ, and Sher A. The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. *Nat Immunol* 9: 1279–1287, 2008.
19. Fesus L, Horvath A, and Harsfalvi J. Interaction between tissue transglutaminase and phospholipid vesicles. *FEBS Lett* 155: 1–5, 1983.
20. Franchi L, Eigenbrod T, Munoz-Planillo R, and Nunez G. The inflammasome: A caspase-1-activation platform that regulates immune responses and disease pathogenesis. *Nat Immunol* 10: 241–247, 2009.
21. Franchi L, Eigenbrod T, and Nunez G. Cutting edge: TNF-alpha mediates sensitization to ATP and silica via the NLRP3 inflammasome in the absence of microbial stimulation. *J Immunol* 183: 792–796, 2009.
22. Fukuda T, Ahearn M, Roberts A, Mattaliano RJ, Zaal K, Ralston E, Plotz PH, and Raben N. Autophagy and mis-targeting of therapeutic enzyme in skeletal muscle in Pompe disease. *Mol Ther* 14: 831–839, 2006.
23. Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, Ralston E, Plotz PH, and Raben N. Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. *Ann Neurol* 59: 700–708, 2006.
24. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, and Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* 12: 119–131.
25. Glass CK, Saijo K, Winner B, Marchetto MC, and Gage FH. Mechanisms underlying inflammation in neurodegeneration. *Cell* 140: 918–934.
26. Glick D, Barth S, and Macleod KF. Autophagy: Cellular and molecular mechanisms. *J Pathol* 221: 3–12.
27. Gozuacik D and Kimchi A. Autophagy and cell death. *Curr Top Dev Biol* 78: 217–245, 2007.
28. Grivennikov SI, Greten FR, and Karin M. Immunity, inflammation, and cancer. *Cell* 140: 883–899, 2010.
29. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM, Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, and Schreiber S. A genome-wide association scan of non-synonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. *Nat Genet* 39: 207–211, 2007.
30. Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, Suzuki-Migishima R, Yokoyama M, Mishima K, Saito I, Okano H, and Mizushima N. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. *Nature* 441: 885–889, 2006.
31. Harris J, Hope JC, and Lavelle EC. Autophagy and the immune response to TB. *Transbound Emerg Dis* 56: 248–254, 2009.



32. Hitomi J, Christofferson DE, Ng A, Yao J, Degterev A, Xavier RJ, and Yuan J. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. *Cell* 135: 1311–1323, 2008.
33. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, Fitzgerald KA, and Latz E. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. *Nat Immunol* 9: 847–856, 2008.
34. Howard J. The IRG proteins: A function in search of a mechanism. *Immunobiology* 213: 367–375, 2008.
35. Huang J, Canadien V, Lam GY, Steinberg BE, Dinanuer MC, Magalhaes MA, Glogauer M, Grinstein S, and Brumell JH. Activation of antibacterial autophagy by NADPH oxidases. *Proc Natl Acad Sci USA* 106: 6226–6231, 2009.
36. Iyer SS, Pulsikens WP, Sadler JJ, Butter LM, Teske GJ, Ulland TK, Eisenbarth SC, Florquin S, Flavell RA, Leemans JC, and Sutterwala FS. Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome. *Proc Natl Acad Sci USA* 106: 20388–20393, 2009.
37. Jin S, DiPaola RS, Mathew R, and White E. Metabolic catastrophe as a means to cancer cell death. *J Cell Sci* 120: 379–383, 2007.
38. Jin S and White E. Role of autophagy in cancer: Management of metabolic stress. *Autophagy* 3: 28–31, 2007.
39. Jin S and White E. Tumor suppression by autophagy through the management of metabolic stress. *Autophagy* 4: 563–566, 2008.
40. Klionsky DJ. Autophagy: From phenomenology to molecular understanding in less than a decade. *Nat Rev Mol Cell Biol* 8: 931–937, 2007.
41. Koike M, Shibata M, Waguri S, Yoshimura K, Tanida I, Kominami E, Gotow T, Peters C, von Figura K, Mizushima N, Saftig P, and Uchiyama Y. Participation of autophagy in storage of lysosomes in neurons from mouse models of neuronal ceroid-lipofuscinoses (Batten disease). *Am J Pathol* 167: 1713–1728, 2005.
42. Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, Tanida I, Ueno T, Koike M, Uchiyama Y, Kominami E, and Tanaka K. Loss of autophagy in the central nervous system causes neurodegeneration in mice. *Nature* 441: 880–884, 2006.
43. Komatsu M, Waguri S, Ueno T, Iwata J, Murata S, Tanida I, Ezaki J, Mizushima N, Ohsumi Y, Uchiyama Y, Kominami E, Tanaka K, and Chiba T. Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice. *J Cell Biol* 169: 425–434, 2005.
44. Kono H and Rock KL. How dying cells alert the immune system to danger. *Nat Rev Immunol* 8: 279–289, 2008.
45. Kroemer G, Galluzzi L, and Brenner C. Mitochondrial membrane permeabilization in cell death. *Physiol Rev* 87: 99–163, 2007.
46. Lee HK, Lund JM, Ramanathan B, Mizushima N, and Iwasaki A. Autophagy-dependent viral recognition by plasmacytoid dendritic cells. *Science* 315: 1398–1401, 2007.
47. Lee HK, Mattei LM, Steinberg BE, Alberts P, Lee YH, Chervonsky A, Mizushima N, Grinstein S, and Iwasaki A. *In vivo* requirement for Atg5 in antigen presentation by dendritic cells. *Immunity* 32: 227–239, 2010.
48. Lee J, Kim YS, Choi DH, Bang MS, Han TR, Joh TH, and Kim SY. Transglutaminase 2 induces nuclear factor-kappaB activation via a novel pathway in BV-2 microglia. *J Biol Chem* 279: 53725–53735, 2004.
49. Lee JY, Nagano Y, Taylor JP, Lim KL, and Yao TP. Disease-causing mutations in parkin impair mitochondrial ubiquitination, aggregation, and HDAC6-dependent mitophagy. *J Cell Biol* 189: 671–679, 2010.
50. Levine B. Eating oneself and uninvited guests: Autophagy-related pathways in cellular defense. *Cell* 120: 159–162, 2005.
51. Levine B and Deretic V. Unveiling the roles of autophagy in innate and adaptive immunity. *Nat Rev Immunol* 7: 767–777, 2007.
52. Levine B and Kroemer G. Autophagy in the pathogenesis of disease. *Cell* 132: 27–42, 2008.
53. Li C, Capan E, Zhao Y, Zhao J, Stolz D, Watkins SC, Jin S, and Lu B. Autophagy is induced in CD4+ T cells and important for the growth factor-withdrawal cell death. *J Immunol* 177: 5163–5168, 2006.
54. Liang C, Lee JS, Inn KS, Gack MU, Li Q, Roberts EA, Vergne I, Deretic V, Feng P, Akazawa C, and Jung JU. Beclin1-binding UVRAG targets the class C Vps complex to coordinate autophagosome maturation and endocytic trafficking. *Nat Cell Biol* 10: 776–787, 2008.
55. Maiuri MC, Tasdemir E, Ciriello A, Morselli E, Vicencio JM, Carnuccio R, and Kroemer G. Control of autophagy by oncogenes and tumor suppressor genes. *Cell Death Differ* 16: 87–93, 2009.
56. Majai G, Petrovski G, and Fesus L. Inflammation and the apopto-phagocytic system. *Immunol Lett* 104: 94–101, 2006.
57. Majno G and Joris I. Apoptosis, oncosis, and necrosis. An overview of cell death. *Am J Pathol* 146: 3–15, 1995.
58. Mann AP, Verma A, Sethi G, Manavathi B, Wang H, Fok JY, Kunnumakkara AB, Kumar R, Aggarwal BB, and Mehta K. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: Delineation of a novel pathway. *Cancer Res* 66: 8788–8789, 2006.
59. Mantovani A, Allavena P, Sica A, and Balkwill F. Cancer-related inflammation. *Nature* 454: 436–444, 2008.
60. Marciniak SJ and Ron D. Endoplasmic reticulum stress signaling in disease. *Physiol Rev* 86: 1133–1149, 2006.
61. Martinon F. Signaling by ROS drives inflammasome activation. *Eur J Immunol* 40: 616–619, 2010.
62. Massey AC, Zhang C, and Cuervo AM. Chaperone-mediated autophagy in aging and disease. *Curr Top Dev Biol* 73: 205–235, 2006.
63. Matsuda N, Sato S, Shiba K, Okatsu K, Saisho K, Gautier CA, Sou YS, Saiki S, Kawajiri S, Sato F, Kimura M, Komatsu M, Hattori N, and Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. *J Cell Biol* 189: 211–221, 2010.
64. McCarroll SA, Huett A, Kuballa P, Chlewicki SD, Landry A, Goyette P, Zody MC, Hall JL, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, and Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM expression and Crohn's disease. *Nat Genet* 40: 1107–1112, 2008.
65. Mills KH and Dunne A. Immune modulation: IL-1, master mediator or initiator of inflammation. *Nat Med* 15: 1363–1364, 2009.
66. Mizushima N. Collaboration of proteolytic systems. *Autophagy* 3: 179–180, 2007.
67. Mizushima N, Yoshimori T, and Levine B. Methods in mammalian autophagy research. *Cell* 140: 313–326, 2010.
68. Monie TP, Bryant CE, and Gay NJ. Activating immunity: Lessons from the TLRs and NLRs. *Trends Biochem Sci* 34: 553–561, 2009.

69. Moscat J and Diaz-Meco MT. The atypical PKC scaffold protein P62 is a novel target for anti-inflammatory and anti-cancer therapies. *Adv Enzyme Regul* 42: 173–179, 2002.
70. Narendra D, Tanaka A, Suen DF, and Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* 183: 795–803, 2008.
71. Narendra DP, Jin SM, Tanaka A, Suen DF, Gautier CA, Shen J, Cookson MR, and Youle RJ. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biol* 8: e1000298, 2010.
72. Ozpolat B, Akar U, Mehta K, and Lopez-Berestein G. PKC delta and tissue transglutaminase are novel inhibitors of autophagy in pancreatic cancer cells. *Autophagy* 3: 480–483, 2007.
73. Petrovski G, Zahuczky G, Katona K, Vereb G, Martinet W, Nemes Z, Bursch W, and Fesus L. Clearance of dying autophagic cells of different origin by professional and non-professional phagocytes. *Cell Death Differ* 14: 1117–1128, 2007.
74. Petrovski G, Zahuczky G, Majai G, and Fesus L. Phagocytosis of cells dying through autophagy evokes a pro-inflammatory response in macrophages. *Autophagy* 3: 509–511, 2007.
75. Qu X, Yu J, Bhagat G, Furuya N, Hibshoosh H, Troxel A, Rosen J, Eskelinen EL, Mizushima N, Ohsumi Y, Cattoretti G, and Levine B. Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. *J Clin Invest* 112: 1809–1820, 2003.
76. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, and Levine B. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. *Cell* 128: 931–946, 2007.
77. Raben N, Shea L, Hill V, and Plotz P. Monitoring autophagy in lysosomal storage disorders. *Methods Enzymol* 453: 417–449, 2009.
78. Ralston SH. Pathogenesis of Paget's disease of bone. *Bone* 43: 819–825, 2008.
79. Rich KA, Burkett C, and Webster P. Cytoplasmic bacteria can be targets for autophagy. *Cell Microbiol* 5: 455–468, 2003.
80. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, and Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. *Nat Genet* 39: 596–604, 2007.
81. Rouschop KM, Ramaekers CH, Schaaf MB, Keulers TG, Savelkoul KG, Lambin P, Koritzinsky M, and Wouters BG. Autophagy is required during cycling hypoxia to lower production of reactive oxygen species. *Radiother Oncol* 92: 411–416, 2009.
82. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, and Akira S. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. *Nature* 456: 264–268, 2008.
83. Schmid D and Munz C. Innate and adaptive immunity through autophagy. *Immunity* 27: 11–21, 2007.
84. Schroder K and Tschopp J. The inflammasomes. *Cell* 140: 821–832, 2010.
85. Schroder K, Zhou R, and Tschopp J. The NLRP3 inflammasome: A sensor for metabolic danger? *Science* 327: 296–300, 2010.
86. Settembre C, Annunziata I, Spanpanato C, Zarcone D, Cobellis G, Nusco E, Zito E, Tacchetti C, Cosma MP, and Ballabio A. Systemic inflammation and neurodegeneration in a mouse model of multiple sulfatase deficiency. *Proc Natl Acad Sci U S A* 104: 4506–4511, 2007.
87. Settembre C, Fraldi A, Rubinsztein DC, and Ballabio A. Lysosomal storage diseases as disorders of autophagy. *Autophagy* 4: 113–114, 2008.
88. Singh SB, Davis AS, Taylor GA, and Deretic V. Human IRGM induces autophagy to eliminate intracellular mycobacteria. *Science* 313: 1438–1441, 2006.
89. Strawbridge AB and Blum JS. Autophagy in MHC class II antigen processing. *Curr Opin Immunol* 19: 87–92, 2007.
90. Suh DA, Giddings TH, Jr., and Kirkegaard K. Remodeling the endoplasmic reticulum by poliovirus infection and by individual viral proteins: An autophagy-like origin for virus-induced vesicles. *J Virol* 74: 8953–8965, 2000.
91. Suzuki T and Nunez G. A role for Nod-like receptors in autophagy induced by Shigella infection. *Autophagy* 4: 73–75, 2008.
92. Szondy Z, Sarang Z, Molnar P, Nemeth T, Piacentini M, Mastroberardino PG, Falasca L, Aeschlimann D, Kovacs J, Kiss I, Szegezdi E, Lakos G, Rajnavolgyi E, Birckbichler PJ, Melino G, and Fesus L. Transglutaminase 2<sup>-/-</sup> mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. *Proc Natl Acad Sci USA* 100: 7812–7817, 2003.
93. Tal MC, Sasai M, Lee HK, Yordy B, Shadel GS, and Iwasaki A. Absence of autophagy results in reactive oxygen species-dependent amplification of RLR signaling. *Proc Natl Acad Sci USA* 106: 2770–2775, 2009.
94. Talloczy Z, Jiang W, Virgin HW, Leib DA, Scheuner D, Kaufman RJ, Eskelinen EL, and Levine B. Regulation of starvation- and virus-induced autophagy by the eIF2alpha kinase signaling pathway. *Proc Natl Acad Sci USA* 99: 190–195, 2002.
95. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, and Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. *Cell Death Differ* 16: 175–183, 2009.
96. Toth B, Garabuczi E, Sarang Z, Vereb G, Vamosi G, Aeschlimann D, Blasko B, Becsi B, Erdodi F, Lacy-Hulbert A, Zhang A, Falasca L, Birge RB, Balajthy Z, Melino G, Fesus L, and Szondy Z. Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. *J Immunol* 182: 2084–2092, 2009.
97. Trombetta ES and Mellman I. Cell biology of antigen processing *in vitro* and *in vivo*. *Annu Rev Immunol* 23: 975–1028, 2005.
98. Uhl M, Kepp O, Jusforgues-Saklani H, Vicencio JM, Kroemer G, and Albert ML. Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8<sup>+</sup> T cells. *Cell Death Differ* 16: 991–1005, 2009.
99. Ullman E, Fan Y, Stawowczyk M, Chen HM, Yue Z, and Zong WX. Autophagy promotes necrosis in apoptosis-deficient cells in response to ER stress. *Cell Death Differ* 15: 422–425, 2008.
100. van der Bruggen P and Van den Eynde BJ. Processing and presentation of tumor antigens and vaccination strategies. *Curr Opin Immunol* 18: 98–104, 2006.
101. Virgin HW and Levine B. Autophagy genes in immunity. *Nat Immunol* 10: 461–470, 2009.
102. White E and DiPaola RS. The double-edged sword of autophagy modulation in cancer. *Clin Cancer Res* 15: 5308–5316, 2009.

103. Wooten MW, Seibenhener ML, Mamidipudi V, Diaz-Meco MT, Barker PA, and Moscat J. The atypical protein kinase C-interacting protein p62 is a scaffold for NF-kappaB activation by nerve growth factor. *J Biol Chem* 276: 7709–7712, 2001.
104. Wu FX, Wu LJ, Luo XY, Yang MH, Tang Z, Xie CM, Zhou JG, Guan JL, and Yuan GH. Expression of FLICE-inhibitory protein in synovial tissue and its association with synovial inflammation in juvenile idiopathic arthritis. *Chin Med Sci J* 25: 20–26, 2010.
105. Xu Y, Kim SO, Li Y, and Han J. Autophagy contributes to caspase-independent macrophage cell death. *J Biol Chem* 281: 19179–19187, 2006.
106. Yoshikawa Y, Ogawa M, Hain T, Yoshida M, Fukumatsu M, Kim M, Mimuro H, Nakagawa I, Yanagawa T, Ishii T, Kakizuka A, Sztul E, Chakraborty T, and Sasakawa C. *Listeria monocytogenes* ActA-mediated escape from autophagic recognition. *Nat Cell Biol* 11: 1233–1240, 2009.
107. Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, and Brumell JH. The adaptor protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. *J Immunol* 183: 5909–5916, 2009.
108. Zhou R, Tardivel A, Thorens B, Choi I, and Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. *Nat Immunol* 11: 136–140, 2010.

Address correspondence to:

Dr. Goran Petrovski

Department of Biochemistry and Molecular Biology

Medical and Health Science Center

Egyetem ter 1, Life Science Building

University of Debrecen

H-4010 Debrecen

Hungary

E-mail: fesus@indi.biochem.dote.hu

Date of first submission to ARS Central, August 16, 2010; date of acceptance, September 2, 2010.

#### Abbreviations Used

AID = atypical PKC interaction domain  
 aPKC = atypical protein kinase C  
 ASC = apoptosis-associated speck-like protein containing a caspase recruitment domain  
 Atg = autophagy  
 CD = Crohn's disease  
 DAMPs = damage-associated molecular patterns  
 DC = dendritic cell  
 DSS = dextran sulfate  
 eIF-2 $\alpha$  = eukaryotic translation initiation factor-2 $\alpha$   
 ER = endoplasmic reticulum  
 FLIP = FADD-like anti-apoptotic molecule  
 G-CSF = granulocyte colony-stimulating factor

HDAC = histone deacetylase  
 HMGB1 = high-mobility group box 1 protein  
 HOPS = homotypic vacuole fusion and protein sorting  
 IFN = interferon  
 IKK = I $\kappa$ B kinase  
 IL = interleukin  
 IL-1R = IL-1 type I receptor  
 IPS = interferon  $\beta$  promoter stimulator 1  
 IRF = interferon regulatory transcription factor  
 IRGM = immunity-related GTPase M  
 JIA = juvenile idiopathic arthritis  
 LC3 = microtubule-associated protein1 light chain 3  
 LPD = lipopolysaccharide  
 LSDs = lysosomal storage diseases  
 MDA5 = melanoma-differentiation associated gene  
 MFGE8 = milk-fat globule EGF-factor  
 MHC = major histocompatibility complex  
 mTOR = mammalian target of rapamycin  
 NALP = NACHT-LRR-PYD-containing protein  
 NF- $\kappa$ B = nuclear factor kappa-light-chain-enhancer of activated B cells  
 NGF = nerve growth factor  
 NGFR = NGF-receptor  
 NLRP3 = NLR family, pyrin domain containing 3  
 NLRs = NOD (nucleotide oligomerization domain)-like receptors  
 P13K = class III phosphatidylinositol-3-kinase  
 PAMPs = pathogen-associated molecular patterns  
 PD = Parkinson's disease  
 PDB = Paget's disease of bone  
 PE = phosphatidyl-ethanolamine  
 PINK = PTEN-induced putative kinase  
 PKC $\delta$  = protein kinase C delta  
 PKR = protein kinase R  
 RIP = receptor-interacting protein  
 RLRs = RIG (retinoic acid inducible gene)-I-like receptors  
 ROS = reactive oxygen species  
 SNARE = soluble N-ethylmaleimide-sensitive factor attachment protein receptor  
 SQSTM1 = sequestosome 1  
 TBK = tank-binding kinase  
 TG2 = transglutaminase 2  
 TGF $\beta$  = transforming growth factor beta  
 TLRs = Toll-like receptors  
 TNF- $\alpha$  = tumor necrosis factor  $\alpha$   
 TRAF = TNF-receptor associated factor  
 TRIF = TIR-domain-containing adapter-inducing interferon- $\beta$   
 UVRAG = UV radiation resistance-associated gene protein  
 VAMP8 = vesicle-associated membrane protein 8





**This article has been cited by:**

1. Antero Salminen, Johanna Ojala, Kai Kaarniranta, Anu Kauppinen. 2012. Mitochondrial dysfunction and oxidative stress activate inflammasomes: impact on the aging process and age-related diseases. *Cellular and Molecular Life Sciences* **69**:18, 2999-3013. [[CrossRef](#)]
2. Kati Kinnunen, Goran Petrovski, Morten C. Moe, András Berta, Kai Kaarniranta. 2012. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. *Acta Ophthalmologica* **90**:4, 299-309. [[CrossRef](#)]
3. Bo XIANG, Mei YI, Xiao-Ling LI, Gui-Yuan LI. 2012. Progress on Role of Autophagy in Cancer\*. *PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS* **39**:3, 241-249. [[CrossRef](#)]
4. Dipak K. Das . 2011. Autophagy: A Story of Live or Let Die. *Antioxidants & Redox Signaling* **14**:11, 2163-2164. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]